Evolus, Inc. (NASDAQ:EOLS) Position Increased by GSA Capital Partners LLP

GSA Capital Partners LLP increased its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 335.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 120,964 shares of the company's stock after buying an additional 93,176 shares during the quarter. GSA Capital Partners LLP owned about 0.19% of Evolus worth $1,960,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. raised its holdings in shares of Evolus by 0.9% during the third quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company's stock worth $15,480,000 after purchasing an additional 8,452 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in shares of Evolus by 6.3% during the 3rd quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company's stock valued at $14,659,000 after buying an additional 53,605 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Evolus in the first quarter worth about $11,628,000. Armistice Capital LLC acquired a new stake in Evolus during the second quarter worth about $3,906,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in Evolus by 5.7% in the second quarter. Cubist Systematic Strategies LLC now owns 338,254 shares of the company's stock valued at $3,670,000 after acquiring an additional 18,157 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EOLS has been the topic of several analyst reports. Barclays raised their price target on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, September 13th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Friday, September 13th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Evolus in a report on Monday, September 16th.

Evolus Trading Down 1.5 %

NASDAQ:EOLS traded down $0.19 during trading hours on Wednesday, hitting $12.25. The company had a trading volume of 695,600 shares, compared to its average volume of 591,308. The company has a 50-day moving average of $16.10 and a 200 day moving average of $13.89. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a market cap of $775.68 million, a P/E ratio of -13.57 and a beta of 1.31. Evolus, Inc. has a 1 year low of $8.31 and a 1 year high of $17.82.

Insider Activity

In related news, CFO Sandra Beaver sold 3,276 shares of the company's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company's stock, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.10% of the company's stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.